Sutezolid is an oxazolidinone antibiotic currently in development as a treatment for extensively drug-resistant tuberculosis. As an inhibitor of bacterial protein synthesis, this therapeutic agent is the… Read more






Sutezolid is an oxazolidinone antibiotic currently in development as a treatment for extensively drug-resistant tuberculosis. As an inhibitor of bacterial protein synthesis, this therapeutic agent is the subject of rigorous pharmaceutical analysis, necessitating access to high-quality reference standards for accurate evaluation. This category provides essential materials for drug development and quality control, including the active pharmaceutical ingredient, related pharmacopeial and non-pharmacopeial impurities, and structural analogs like PNU-101603. Furthermore, stable isotope labelled compounds are available to serve as internal standards during mass spectrometry-based bioanalysis, aiding in precise impurity profiling and method validation. By utilizing these characterized reference materials, analytical laboratories can ensure compliance with regulatory standards throughout the lifecycle of drug research and manufacturing, supporting the comprehensive assessment of purity, stability, and pharmacokinetic performance in both clinical and preclinical environments.